Peptomyc: Funding, Investors & Team (Sep 2026)

Peptomyc is a company focused on the development of a new generation of cell-penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment. The company was founded in December 2014 and it is based on Dr. Soucek’s scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years. Currently, cancer incidence in the world exceeds 14 million cases per year and results in 8 million deaths annually. Moreover, such numbers are forecast to rise by 75% over the next 20 years (World Cancer Report. International Agency for Research on Cancer 2014). At the moment, standard therapies include surgery, radiotherapy, chemotherapy, and, in a restricted subset of cancers, precision medicine. Unfortunately, very often these therapies fail, due to the development of resistance. Peptomyc has adopted a different strategy based on the inhibition of the oncoprotein Myc, which is found deregulated in the majority of human cancers. Myc holds a non-redundant function in cancer around which tumors cannot evolve, hence targeting Myc is the most promising therapeutic opportunity to date. Although Myc plays a central role in cancer there is currently no Myc inhibitor in the market.

Peptomyc has raised $14.3M across 2 rounds on record. The most recent is an undisclosed round of $2.9M announced in Jan 2022.

Peptomyc's most recent funding round on record is an undisclosed round of $2.9M, announced in Jan 2022.

Laura Soucek is listed as CEO at Peptomyc.

Peptomyc is based in Barcelona, Catalonia, Spain.

Peptomyc is in the 11-50 employee band.

Peptomyc's latest round of $2.9M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.